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Resistance to TGFβ suppression and improved anti-
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Transforming growth factor β (TGFβ) is important in maintaining self-tolerance and inhibits T
cell reactivity. We show that CD8+ T cells that lack the tyrosine phosphatase Ptpn22, a major
predisposing gene for autoimmune disease, are resistant to the suppressive effects of TGFβ.
Resistance to TGFβ suppression, while disadvantageous in autoimmunity, helps Ptpn22−/−
T cells to be intrinsically superior at clearing established tumors that secrete TGFβ.
Mechanistically, loss of Ptpn22 increases the capacity of T cells to produce IL-2, which
overcomes TGFβ-mediated suppression. These data suggest that a viable strategy to improve
anti-tumor adoptive cell therapy may be to engineer tumor-restricted T cells with mutations
identiﬁed as risk factors for autoimmunity.
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T cell immune tolerance is maintained in the periphery by acombination of extrinsic factors, including the action ofregulatory T cells (Treg) and suppressive cytokines such as
transforming growth factor β (TGFβ). TGFβ cytokines are posi-
tive and negative regulators of proliferation and differentiation in
many cell lineages, and play a key role in maintaining peripheral
T cell tolerance1. TGFβ signaling was shown to be essential to
maintain peripheral T cell quiescence in vivo2–5 and to be a
negative regulator of T cell proliferation in vitro6. Mice whose
T cells are unresponsive to TGFβ signals either by expressing a
dominant negative TGFβRII transgene2,4, or through speciﬁc T
cell deletion of the TGFβ receptor, Tgfbr13,5 die from fatal lym-
phoproliferative disease. In the absence of TGFβ signaling, per-
ipheral CD4+ and CD8+ T cells become activated in a cell-
intrinsic fashion, most likely due to homeostatic expansion from
the lymphopenic environment shortly after birth, and develop
effector function and pathogenicity7,8. Thus, TGFβ signals are
particularly important for the regulation of the TCR-mediated,
weak, self-ligand interactions that maintain peripheral T cell
homeostasis.
TGFβ signaling is important also in restricting T cell responses
to tumors9,10. In the context of CD8+ T cells, TGFβ targets the
transcription of key effector molecules and interferes with their
ability to kill tumor cells10. These observations have led to the
suggestion that targeting TGFβ sensitivity, for example, by inac-
tivating the TGFβ receptor in T cells, could be beneﬁcial in anti-
tumor T cell therapy11.
There are several parallels between the induction of T cell
autoimmunity and effective tumor immunosurveillance12,13.
T cells in autoimmune disease display functional characteristics
that, in a tumor setting, may be beneﬁcial. For example, auto-
reactive T cells respond effectively to poorly immunogenic anti-
gens and are resistant to immune-regulatory mechanisms2,8.
Similarly, in order to mount effective anti-cancer responses,
T cells need to overcome a strongly inhibitory tumor micro-
environment, characterized by the presence of Tregs and high
levels of inhibitory cytokines such as TGFβ. Indeed, TGFβ is
expressed by a wide range of cancer cell types (https://portals.
broadinstitute.org/ccle/home) as well as by tumor-inﬁltrating
immune cells such as myeloid-derived suppressor cells14.
Genome-wide association studies have shown that the hema-
topoietic tyrosine phosphatase, PTPN22, has a commonly
expressed variant, PTPN22R620W, that is highly associated with
predisposition to a number of autoimmune diseases15,16. PTPN22
regulates Ag-speciﬁc T- and B-cell responses and some pattern
recognition signaling pathways in myeloid cells that lead to
production of type 1 interferons15. We showed previously that
mouse Ptpn22−/− T cells are partially resistant to wild-type Treg-
mediated suppression17 and are more responsive to low-afﬁnity
antigens18. Given the critical dual role of TGFβ in limiting
autoimmune and anti-tumor responses, we investigated the
impact of PTPN22 deﬁciency on the responses of CD8+ T cells to
this key inhibitory cytokine. Furthermore, we sought to test the
hypothesis that PTPN22 acts as a brake to limit the effectiveness
of anti-tumor T cell responses. We show that Ptpn22−/− CD8
T cells are considerably more resistant to the suppressive effects
of TGFβ than WT T cells. Concentrations of TGFβ that suppress
proliferation and differentiation of effector cytokines in WT
T cells show little inhibition of these processes in Ptpn22−/− CD8
T cells. Upon stimulation with both weak and strong agonists
peptides Ptpn22−/− CD8 T cells produce more IL-2 than WT
T cells and IL-2 interferes with the suppressive effect of TGFβ.
Consequently upon adoptive transfer, Ptpn22−/− CD8 T cells are
better able than WT CD8 T cells to control the growth of
established tumors that secrete TGFβ. Importantly, the superior
anti-tumor capacity of Ptpn22−/− CD8+ T cells is observed in
response to both strong and weak antigens, the latter being a
common trait of tumor-associated antigens, which can otherwise
limit robust anti-tumor immune responses. These results suggest
that targeting genes associated with susceptibility to auto-
immunity may be a viable strategy to improve the efﬁcacy of
adoptive T cell immunotherapy.
Results
Ptpn22−/− T cells resist TGFβ-mediated suppression. TGF-β
was shown previously to suppress low-afﬁnity T cell responses more
effectively than high-afﬁnity responses8 and we showed a similar
role for PTPN22 in limiting CD8+ T cell responses18. Using the
OVA-speciﬁc TCR transgenic mouse, OT-1 on a Rag-1−/− back-
ground (hereafter called OT-1 T cells), for which a number of
peptides have been characterized, which span a range of afﬁnities19,
we examined the sensitivity of control and Ptpn22−/− OT-1 T cells
to inhibition by TGFβ in vitro.
As reported previously8, TGFβ markedly inhibited antigen-
induced proliferation of OT-1 TCR transgenic T cells in a dose-
dependent manner (Fig. 1a–c). This suppression occurred
following stimulation both with strong agonist, SIINFEKL (N4)
peptide and with weak agonist, SIITFEKL (T4) peptide. Enhanced
proliferation of Ptpn22−/− OT-1 T cells compared to control OT-
1 cells was particularly apparent in response to weak agonist
peptide, T4, in the absence of TGFβ (Fig. 1a–c), as we reported
previously18. Signiﬁcantly, both N4- and T4-induced proliferation
of Ptpn22−/− OT-1 T cells were extremely refractory to TGFβ
inhibition (Fig. 1a–c) compared to control OT-1 T cells. In
response to N4 peptide, no inhibition of Ptpn22−/− OT-1 T cell
proliferation was seen at doses of up to 5 ng/ml TGFβ, while in
response to T4 peptide, Ptpn22−/− OT-1 T cells required ~10-fold
higher concentrations of TGFβ than control OT-1 T cells to show
equivalent suppression of proliferation.
The mechanism of TGFβ-mediated suppression of T cell
responses is not well understood. PTPN22 is known to target
signaling molecules immediately downstream of the TCR, such as
Lck and ZAP70, so it was unclear why Ptpn22−/− T cells would be
more resistant than control T cells to TGFβ-mediated suppres-
sion. We asked at what point TGFβ suppression acted to inhibit
control OT-1 T cells. Time-course analysis demonstrated that
TGFβ inhibition of OT-1 T cell proliferation was apparent at day
3 (Fig. 1d), but in order to achieve this, TGFβ needed to be
present from the start of culture. Delaying addition of TGFβ by
2 days failed to limit antigen-induced proliferation (Fig. 1e).
Similarly, TGFβ-mediated inhibition of OT-1 T cell proliferation
could be alleviated by an inhibitor to the TGFβ receptor, but only
when added from the beginning of culture (Fig. 1f).
These data show that TGFβ acted early in T cell activation, as
by 48 h after stimulation cells were resistant to the anti-
proliferative effects of TGFβ. Accordingly, we analyzed activation
marker and transcription factor expression at 24 h following
stimulation of OT-1 T cells. In control OT-1 T cells, TGFβ
limited the extent of weak agonist T4-induced upregulation of the
IL-2 receptor-α chain (CD25), and key transcription factors Myc
and IRF4, but less so Tbet, whereas Ptpn22−/− OT-1 T cells were
refractory to these inhibitory effects of TGFβ (Fig. 2a, b). These
data indicate that loss of PTPN22 counteracted TGFβ inhibition
during the early phase of TCR engagement.
Ptpn22−/− CD8+ T cells are superior at tumor clearance. The
resistance of Ptpn22−/− T cells to TGFβ-mediated suppression
in vitro led us to ask whether these CD8+ T cells would be more
effective for adoptive cell therapy against TGFβ-secreting tumors
in vivo. First, we evaluated the ability of control and Ptpn22−/−
OT-1 T cells to reject EL4 lymphoma cells (EL4-OVA) expressing
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high-afﬁnity N4 peptide as a tumor-speciﬁc antigen. EL4-OVA
tumors were established subcutaneously for 5d before transfer of
small numbers (5 × 104/mouse) of either control or Ptpn22−/−
naive OT-1 T cells. Tumor size was monitored for a further 7d
after which mice were killed to prevent control animals exceeding
permitted tumor volumes, and wet tumor mass measured.
Strikingly, Ptpn22−/− OT-1 T cells were signiﬁcantly superior to
control cells in controlling growth of subcutaneous EL4-OVA
tumors (*p< 0.05 using two-way ANOVA with Tukey’s post test)
(Fig. 3a). In particular, very few animals receiving Ptpn22−/− OT-
1 T cells showed evidence of tumor mass over the time course
following transfer, whereas a number of those receiving control
OT-1 T cells showed ongoing tumor growth followed by regres-
sion toward the end of the experiment.
TGFβ is secreted by EL4 cells, so we asked to what extent TGFβ
was preventing tumor rejection by OT-1 T cells2,20–22. Sub-
cutaneous tumors were established as before, but with an EL4-
OVA cell line engineered to express a soluble form of the
TGFβRII (EL4-OVA STβRII)10. Adoptively transferred control
OT-1 T cells were better able to reduce tumor growth when TGFβ
was blocked, as shown previously10, while Ptpn22−/− OT-1 T cells
effected complete rejection of EL4-OVA STβRII cells (20/20
mice) (Fig. 3b). These data illustrate that while, not completely
immune to TGFβ inhibition, Ptpn22−/− T cells are inherently
superior in managing growth of TGFβ-secreting tumors.
Key to control of tumor mass is the ability of CD8+ T cells to
kill tumor targets. TGFβ acts to inhibit the expression of several
cytolytic gene products, thus hindering CD8 T cell cytotoxicity10.
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Fig. 1 Ptpn22 deﬁciency protects cells from TGFβ-mediated suppression. a Dilution of Cell Trace Violet (CTV) in control and Ptpn22−/− OT-1 cells was used
to assess proliferation of cells stimulated with N4 or T4 peptide (10−6M) for 3 days in the presence of varying doses of TGFβ (0–5 ng/ml). b Proliferation
was quantiﬁed by calculation of division index (FlowJo). c Numbers of live control and Ptpn22−/− OT-1 cells recovered after stimulation was calculated
using MACSquant software (mean± s.d. for triplicate replicates). d TGFβ inhibition becomes apparent only after 2d of culture. Dilution of CTV from control
OT-1 cells stimulated with T4 (10−6M)± TGFβ (5 ng/ml) after d1, d2, or d3 of culture. e Dilution of CTV violet from control OT-1 cells stimulated with T4
(10−6M)± TGFβ (5 ng/ml) added at d0 or d2 of culture. f Inhibition of TGFβR1 signaling, by addition of ALK-5/TGFβR1 inhibitor SB431542, at d0 interferes
with TGFβ-mediated suppression of proliferation, but SB431542 is less effective when added on d1 or d2 of culture. Control OT-1 cells stimulated with T4
(10−6M)± TGFβ (5 ng/ml) were cultured for 3d± 5 μM SB431542 (or DMSO vehicle control) added on d0, d1, or d2 of culture. Representative histograms
of CTV dilution analysed by ﬂow cytometry are shown in a, d, e, f. Data are representative of 5 (a–c), 2 (d, e), and 3 (f) separate experiments
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To better mimic responses to weak tumor antigens, we used ID8
murine ovarian carcinoma cells23 that as a tumor-speciﬁc antigen
expressed the weak agonist peptide, T4, which is ~70-fold less
potent in stimulating OT-1 T cells than N4 peptide24, and is of
equivalent afﬁnity to self-peptides that select the thymic
repertoire19. We cultured ID8-T4 cells with control and Ptpn22
−/− OT-1 T cells in vitro and monitored production of granzyme
B (GzB) and IFNγ. Remarkably, while GzB was detectable in less
than 10% of control cells, ~70% of Ptpn22−/− T cells were positive
for GzB and a substantial proportion of the latter also expressed
IFNγ in response to ID8-T4 cells alone. Blockade of TGFβ
signaling by addition of a TGFβ-receptor inhibitor relieved the
suppression of control T cells so that now ~40% expressed
granzyme B while >90% of Ptpn22−/− cells became GzB+
(Fig. 3c).
We then compared the ability of control and Ptpn22−/− OT-1
CD8+ TCR transgenic T cells to respond to tumors expressing
low-afﬁnity TSA in vivo. ID8-T4 tumors were established in the
peritoneum of recipient B6 (CD45.1/CD45.2F1) mice for 28d
before transfer of an equal mixture of control CD45.1+ and
Ptpn22−/− CD45.2+ OT-1 T cells. Three days later, we found
signiﬁcantly enhanced proliferation of Ptpn22−/− OT-1 T cells
compared to control cells in individual mice (Fig. 3d, **p< 0.01
using two-way ANOVA with Tukey’s post test) showing that
Ptpn22−/− T cells indeed proliferate more in response to the weak
T4 antigen expressed by the tumor.
In order to non-invasively assess ID8 tumor growth in vivo, we
transduced ID8-T4 cells with lentivirus-expressing Fireﬂy
luciferase (Fluc), enabling us to monitor bioluminescence as a
correlate of tumor mass. Tumors were established in the
peritoneum of B6 mice prior to adoptive transfer of control or
Ptpn22−/− OT-1 T cells, that were ﬁrst activated in vitro. Tumor
bioluminescence was analyzed 14d post T cell transfer. While
control OT-1 T cells reduced tumor mass in a number of
recipient mice, this effect did not reach statistical signiﬁcance
(Fig. 3e). By contrast, adoptive cell transfer of Ptpn22−/− OT-1
cells resulted in a signiﬁcant decrease in luminescence signal, and
in the majority of mice, a complete rejection of tumor load
(Fig. 3e, *p< 0.05 using two-way ANOVA with Tukey’s post test).
Taken together, our data using EL4 lymphoma and ID8
ovarian carcinoma models indicate that Ptpn22−/− T cells
generate a more effective anti-tumor responses to both high-
and low-afﬁnity TSA. This effect most likely stems from a
combination of the enhanced TCR responsiveness and prolifera-
tion of cells lacking PTPN22 to both high- and low-afﬁnity TSA
and their reduced susceptibility to inhibitory cytokines such as
TGFβ, permitting differentiation and expression of effector
cytokines and the cytolytic machinery.
Canonical TGFβR signaling is unaffected by loss of PTPN22.
We next assessed the mechanisms underlying the ability of
Ptpn22−/− T cells to overcome TGFβ-mediated suppression.
Surface TGFβRII expression (Fig. 4a) and canonical TGFβRII
signaling, judged by TGFβ-induced phospho-SMAD (Fig. 4b),
were identical in control and Ptpn22−/− OT-1 T cells.
No stim
T4 – TGFβ
T4 + TGFβ
100
80
60
40
20
0
CD25
200
150 **** ****
***
*
**
*** Control
Ptpn22–/–
*
100
M
FI
 (n
orm
ali
ze
d)
50
0
TGFβ: –
CD25 cMyc IRF4
+ – + – +
Tbet
– +
cMyc IRF4 Tbet
Control
Ptpn22–/–
Ev
en
ts
 (%
 of
 m
ax
)
100
80
60
40
20
0
0 102 103 104 105
100
80
60
40
20
0
0 102 103 104 105
100
80
60
40
20
0
0102 103 104 1050 102 103 104 105
100
80
60
40
20
0
100
80
60
40
20
0
0 102 103 104 105
100
80
60
40
20
0
0 102 103 104 105
100
80
60
40
20
0
0102 103 104 1050102 103 104 105
CD25 cMyc IRF4 Tbet
b
a
Fig. 2 PTPN22 mediates the extent of TGFβ-mediated suppression of early activation markers. a Control and Ptpn22−/− OT-1 cells were cultured for 24 h
with T4 peptide (10−6M)± TGFβ (5 ng/ml). Activation was assessed by upregulation of CD25 and transcription factors c-Myc, IRF4, Tbet by ﬂow
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with Tukey’s post test for multiple comparisons
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Furthermore, in both genotypes, there was SMAD-dependent
inhibition of granzyme B expression20 and upregulation of CD44
expression by high-dose TGFβ (Fig. 4c). Recent analyses have
shown that expression of the transcription factor FoxP1 is
essential for TGFβ-mediated suppression of anti-tumor T cells25,
however, levels of FoxP1 expression by control and Ptpn22−/−
T cells were comparable under basal and activated conditions
(Fig. 4d).
In order to determine whether TGFβ directly affects PTPN22
function, we analyzed the phosphorylation of well-deﬁned
PTPN22 substrates ZAP70 and TCRζ26 following TCR stimula-
tion of control OT-1 T cells in the presence or absence of TGFβ.
Importantly, TGFβ did not impair basal or TCR-stimulated levels
of Zap70 Y493, TCRζ Y83, or ERK MAPKinase phosphoryation
(Fig. 4e). Previous data have shown that PTPN22 associates with
Csk, which may be important for its function in T cells27.
However, co-immunoprecipitation of PTPN22 with Csk was
unaffected by culture of OT-1 T cells with TGFβ (Fig. 4f).
Together, these data show that PTPN22 does not impact directly
upon canonical SMAD-dependent TGFβ receptor signaling
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Fig. 3 Loss of Ptpn22 improves the response of CD8 T cells to tumors. a, b B6 mice were injected s.c. with 1 × 106 EL4-OVA (a) or EL4-OVAsTβRII cells (b).
Five days later, 5 × 104 control or Ptpn22−/− OT-1 cells were injected i.v. Tumor weight (left panel) and tumor incidence (middle panel) is shown (d12 for
EL4-OVA, d14 for EL4-OVAsTβRII from two pooled experiments, n= 20/group). Right panel shows mean tumor volume of individual mice, which received
no exogenous T cells (black lines), control OT-1 T cells (blue lines), or Ptpn22−/− OT-1 T cells (red lines) until termination of the experiment on d12 (a) or
d14 (b) from one experiment (n= 10/group). c Control and Ptpn22−/− OT-1 cells were co-cultured with ID8 tumor cells±ALK-5/TGFR1 inhibitor
SB431542. After 2 days, Brefeldin A was added to cultures for 6 h and cells were stained for intracellular granzyme B and IFNγ analysis by ﬂow cytometry.
Representative dot plots and quantiﬁcation (mean and s.d. of three replicates) are shown. a–c *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 as
determined using two-way ANOVA with Tukey’s post test for multiple comparisons and for incidence data ***p< 0.001 and ****p< 0.0001 as determined
by χ2-test with Fisher’s exact post test adjusting the p value for number of comparisons. Data are representative of three separate experiments. d Groups
(n= 6) of CD45.1/2 B6 mice were injected i.p. with 1 × 107 ID8 cells, followed 28 days later with an i.p. injection of a mix of CTV-labeled control CD45.1+
OT-1 and Ptpn22−/− CD45.2+ OT-1 cells (1 × 106 of each). Peritoneal lavage was harvested 3 days later and assessed for OT-1 T cell proliferation by ﬂow
cytometry. Division index was calculated using Flowjo software. **P< 0.01 as determined by Student’s paired t test. Data are representative of two
experiments. e Groups (n= 7) of B6 mice were injected i.p. with 5 × 106 ID8-T4-ﬂuc2 cells and assessed for tumor establishment on d11 (pre treatment) by
bioluminescence imaging. On d12, groups of mice received either no cells, 10 × 106 control OT-1 CTLs, or Ptpn22−/− OT-1 CTLs i.p. All mice were assessed
for tumor growth by bioluminescence imaging on d26 (14 d post treatment). Example images of n= 4 mice/group are shown d11 and d26 (pre/post
treatment). Graphs show bioluminescence signal intensity of all mice on d11 and d26 (pre/post treatment). *p< 0.05, ****p< 0.0001, as determined by
Student’s paired t test. Data are representative of two experiments
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pathways or FoxP1-dependent processes, as these are unaffected
in Ptpn22−/− T cells, and conversely that TGFβ does not directly
affect the function of PTPN22 in regulating T cell signaling.
IL-2 protects against TGFβ-mediated suppression. Our data
suggested that indirect mechanisms were likely to underlie the
ability of Ptpn22−/− T cells to resist TGFβ inhibition. Serendipi-
tously, we noted that when control and Ptpn22−/− OT-1 T cells
were activated with T4 peptide as a 1:1 mix in the same culture
wells, the inhibitory effect of TGFβ on control T cell proliferation
was abrogated (Fig. 5a). These data suggested that Ptpn22−/−
T cells secreted or expressed a factor that “rescued” control cells
from the effects of TGFβ in a co-culture system. Culture of
control and Ptpn22−/− T cells in transwells also abrogated
the inhibitory effect of TGFβ on control T cell proliferation,
indicating that a soluble factor was responsible for the
protective effect (Fig. 5a, b). TGFβ was shown to limit T cell IL-2
production20,28,29 and a protective effect of IL-15 and other
common gamma chain cytokines on TGFβ suppression has
been reported7,30. We found that, compared with control cells,
Ptpn22−/− OT-1 T cells secreted signiﬁcantly greater quantities of
IL-2 in response to both strong N4 and weak T4 agonist peptides
(Fig. 5c, ***p< 0.001 and ****p< 0.0001 using two-way ANOVA
with Tukey’s post test). Importantly, TGFβ treatment almost
completely blocked control but not Ptpn22−/− OT-1 T cell IL-2
production (Fig. 5c).
Two distinct approaches conﬁrmed the importance of elevated
TCR-induced IL-2 production for the ability of Ptpn22−/− T cells
to resist TGFβ-mediated inhibition. First, canonical IL-2-
dependent signaling pathways were blocked using the inhibitor
tofacitinib, which inhibits Jak3 in addition to other members of
the Jak kinase family. Tofacitinib markedly reduced the ability of
Ptpn22−/− OT-1 T cells to withstand TGFβ-mediated inhibition,
indicating that IL-2 cytokine receptor signaling was important for
the resistance of Ptpn22−/− cells to TGFβ (Fig. 5d). Second, the
addition of recombinant IL-2 to T cell cultures prevented the
inhibitory effects of TGFβ on OT-1 T cell proliferation when
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added at either d0 or on d2 (Fig. 5e). Recovery of proliferation
was dose dependent (Fig. 5f) conﬁrming that insufﬁciency of IL-2
production in the presence of TGFβ accounted for the inhibition
of OT-1 T cell proliferation. Together, these data strongly suggest
that elevated IL-2 production in response to TCR triggering
enables Ptpn22−/− T cells to overcome the inhibitory effects of
TGFβ.
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Previous studies have suggested that TGFβ interferes with
TCR-induced Ca2+ signaling and subsequent NFAT activation,
thereby limiting T cell activation and IL-2 production31. We have
shown previously that Ca2+ ﬂuxes in naive T cells were not
inﬂuenced by the absence of Ptpn2217. However, in vitro
measurement of Ca2+ ﬂux in primary naive T cells by FACS
requires very acute and strong stimulation, e.g., in the OT-1
model by using multivalent peptide:MHC complexes containing
strong agonist peptide N432. Under these stimulation conditions,
we saw no reduction of Ca2+ signals in control OT-1 T cells in the
presence of TGFβ (Supplementary Fig. 1). However, we reasoned
that looking more downstream, e.g., at NFAT nuclear transloca-
tion might reveal some differences. Indeed, we observed
signiﬁcant inhibition of NFAT nuclear translocation in the
presence of TGFβ when control OT-1 T cells were stimulated
with T4 peptide (Fig. 5g, ****p< 0.0001 using Student’s t test). In
contrast, T4-induced NFATc1 nuclear translocation in stimulated
Ptpn22−/− CD8 T cells was remarkably resistant to suppression
by TGFβ (Fig. 5g). These data corroborate the ﬁnding that TGFβ
suppresses control CD8 T cell proliferation by interfering with IL-
2 production through inhibition of NFAT activation, and indicate
that in the absence of PTPN22, this inhibitory pathway is
circumvented.
Discussion
The ability of T cells to integrate and respond appropriately to a
complex network of signals triggered by antigen receptor
engagement, cytokines, chemokines, and other environmental
signals is critical to the outcome of immune responses. Further-
more, in order to maintain tolerance, cell-intrinsic inhibitory
mechanisms and the action of suppressive cytokines, including
TGFβ prevent T cell activation by low-afﬁnity self-antigens. In
the current work, we found that altering the sensitivity of TCR
signaling, by deletion of the autoimmune-associated phosphatase
PTPN22, further impacted upon the sensitivity of CD8+ T cells to
the suppressive effects of TGFβ. Our results describing the con-
sequent imbalance in positive and negative signaling have
important implications for our understanding of the mechanisms
regulating autoimmune T cells and may also have practical
applications in tumor therapy. In this regard, we showed that the
combination of enhanced TCR sensitivity and subsequent resis-
tance to TGFβ inhibition enabled Ptpn22−/− T cells to have
potent anti-tumor effector function in vivo.
A key mechanism underlying resistance to TGFβ suppression
was the ability of Ptpn22−/− T cells to produce IL-2 more
abundantly than control T cells. Other studies have shown that
Ptpn22−/− CD4+ T cells make more cytokines, including IL-2,
than WT T cells33,34 and we show that is true for Ptpn22−/−
CD8+ cells also. Previous data indicated that Smad3-dependent
inhibition of Il2 transcription and protein expression was key to
TGFβ-induced suppression of TCR-induced T cell proliferation35.
Consistent with this, in our studies, suppression of peptide-
induced control OT-1 T cell proliferation could be reversed by
addition of recombinant IL-2 to cultures. It is worthy of note that
PTPN22 does not directly regulate IL-233 or TGFβ receptor sig-
naling pathways. Therefore, it is likely that the ability of Ptpn22
−/− T cells to withstand TGFβ-induced suppression is a result of
quantitative effects of elevated IL-2 production rather than qua-
litative effects on IL-2R or TGFβR signaling. In addition, our data
highlight the complexity of the interplay between IL-2 and TGFβ
signaling on T cell responses. In this regard, IL-2 abrogates the
pro-inﬂammatory effects of TGFβ on CD4+ Th17 differentiation
and instead favors inducible Treg expansion36. By contrast, our
data show that elevated IL-2 production by CD8+ T cells abro-
gates suppressive effects of TGFβ and instead favors a pro-
inﬂammatory response. Thus, the effects of these two cytokines
in vivo are likely to be highly context dependent.
The mechanisms by which TGFβ inhibits TCR signaling and T
cell function are not fully understood. An early report suggested
that, in CD4+ T cells, TGFβ signals interfere with very early TCR-
induced Tek and ERK kinase activation and NFAT nuclear
translocation31. Our data support this view as we saw clear
inhibition of NFAT translocation in control cells incubated with
TGFβ, whereas Ptpn22−/− T cells were resistant to this inhibiiton.
Analysis of more upstream pathways did not reveal more speci-
ﬁcally how TGFβ inhibition intersects TCR signaling, as we saw
no change in TCRζ, Zap70, or MAPK signaling in WT T cells
stimulated in the presence or absence of TGFβ. However, these
assays utilize strong stimulation of the TCR over very short time
frames and may therefore lack the sensitivity to observe TGFβ
inhibition. More recently, TGFβ-mediated T cell suppression has
been linked to effects on the mTOR pathway37. In those studies,
suppressive effects of TGFβ on mTOR signaling were assessed
following 36 h (or more) of T cell stimulation, time points at
which autocrine IL-2 signals contribute to mTOR activation38.
Therefore, it is possible that TGFβ inhibition of mTOR signals at
these later time points might, at least in part, be explained by
reduced IL-2 secretion. In NK cells, TGFβ also suppresses mTOR
activation with potent downstream effects on cellular metabo-
lism39. Given the importance of shifts in cellular metabolism in
the generation and differentiation of effector T cells, it will be
interesting to determine whether TGFβ also impedes these pro-
cesses in T cells. A recent study indicated that FoxP1 expression
was required for TGFβ-mediated inhibition of anti-tumor CD8+
T cells25. However, our data showed that Ptpn22−/− and control
OT-1 T cells expressed equivalent levels of FoxP1. Therefore, it is
likely that FoxP1 expression is necessary but not sufﬁcient to
mediate TGFβ suppression.
Our experiments provide new insight into the mechanisms by
which PTPN22 dampens T cell activation. Loss of PTPN22
function increases the chance of T cells responding to weak, self-
antigens and this enhanced TCR sensitivity is compounded by a
knock-on effect on the inhibitory TGFβ pathway. While these
effects are likely to be detrimental in the context of autoimmune
disease, they also raise the possibility that GWAS-identiﬁed,
autoimmune susceptibility loci can be manipulated to improve
the intrinsic efﬁcacy of adoptive cell therapy (ACT) for cancer. In
this regard, we showed that Ptpn22−/− T cells were superior to
control cells in responding to both high- and low-afﬁnity TSA
and in mediating tumor rejection in vivo, suggesting that tar-
geting PTPN22 may be a viable approach in T cell immu-
notherapies. We reason that in future studies, by restricting loss
of PTPN22 to tumor-speciﬁc T cells, undesirable autoimmunity
will be minimized. Despite the recent success of chimeric
antigen receptors40, a major advantage of retaining TCR
expression for ACT is that many TSAs are intracellular proteins
that are only presented in the context of MHC. However, TSAs
are frequently too weak to stimulate effective T cell responses, but
by manipulating the intracellular signaling machinery, we
show that it is possible to harness traits that are undesirable in
autoreactive T cells, such as reactivity to weak antigens and
resistance to suppressive cytokines, for the beneﬁt of anti-tumor
responses.
Methods
Mice. Rag-1−/− OT-I CD45.1+/+ 40, Ptpn22−/− Rag-1−/− OT-I CD45.2+/+ 18 and
CD45.1+/−CD45.2+/− mouse strains were bred and maintained under speciﬁc and
opportunistic pathogen-free conditions at the Universities of Edinburgh and Leeds.
Age-matched (6–12 weeks) and sex-matched mice were used in all experiments.
Animal procedures were approved under a UK Home Ofﬁce project license and
were performed in compliance with the ethical guidelines of the Universities of
Edinburgh and Leeds.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01427-1
8 NATURE COMMUNICATIONS | 8:  1343  |DOI: 10.1038/s41467-017-01427-1 |www.nature.com/naturecommunications
Flow cytometry and antibodies. The following conjugated antibodies were used:
phycoerythrin–indotricarbocyanine–anti-CD8β (clone eBioH35-17.2, cat
15266777, 1:400 dilution), phycoerythrin–anti-CD25 (clone PC61.5, cat 15298489,
1:200 dilution), allophycocyanin–eFluor 780–anti-CD44 (clone IM7, cat 15351620,
1:400 dilution), ﬂuorescein isothiocyanate–anti-TCRαβ (clone H57-597, cat 11-
5961-81, 1:200 dilution), phycoerythrin–anti-T-bet (clone 4B10, cat 12-5825-80,
1:100 dilution), eFluor 450–anti-IRF4 (clone 3E4, cat 15519846, 1:200 dilution),
eFluor 450–anti–granzyme B (clone NG2B, cat 15371830, 1:100 dilution), (all from
eBioscience); Alexa Fluor 488–anti-CD25 (clone PC61.5, cat 102018, 1:200 dilu-
tion), allophycocyanin–anti-CD45.1 (clone A20, cat 110713, dilution 1:200),
ﬂuorescein isothiocyanate–anti-CD45.1 (clone A20, cat 110718, dilution 1:200),
phycoerythrin–anti-CD45.2 (clone 104, cat 109807, dilution 1:200), Brilliant Violet
421–anti-CD45.2 (clone 104, cat 109832, dilution 1:200), Alexa Fluor 488–anti-
IFN-γ (clone XMG1.2, cat 505813, dilution 1:200) (all from BioLegend). Uncon-
jugated rabbit antibodies to c-Myc (clone D84C12, cat 5605, dilution 1:50),
phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (clone D27F4, cat D27F4,
dilution 1:100), FoxP1 (clone D35D10 XP, cat 4402, dilution 1:200), phospho-
Zap70 (Tyr493)/Syk (Tyr526) Y493 (cat 2704, dilution 1:100), phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) (clone D13.14.4E, cat 4370, dilution 1:100) were
from Cell Signaling Technologies and anti-CD3 zeta (phospho Y83) (clone EP776
(2)Y, cat ab68236, dilution 1:50) was from Abcam; all were counterstained with
goat anti-rabbit (A21244; Molecular Probes). Phycoerythrin anti-mouse TGFbeta
RII (cat FAB532P, 1:50) and isotype control were from R&D systems. Live/Dead
Aqua and Cell Tracer Violet (CTV) dyes were from Life Technologies. For intra-
cellular staining, cells were ﬁxed in Phosﬂow Lyse/Fix Buffer 1 (BD) or FoxP3 Fix/
Permeabilization Buffer (eBioscience) before staining with antibody in Permeabi-
lization/Wash buffers (eBioscience). For phospho-SMAD2/3, staining cells were
ﬁxed with 2% paraformaldehyde and permeabilized with methanol prior to
staining. Samples were acquired with a MACSQuant ﬂow cytometer (Miltenyi) and
data were analyzed with FlowJo software (Treestar). Division index is the average
number of cell divisions that a cell in the original population has undergone (i.e.,
includes the undivided peak).
T cell culture and stimulation. T cells from the lymph nodes of wild-type and
Ptpn22−/− mice were cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM,
Invitrogen) supplemented with 10% FCS, L-glutamine, antibiotics and 50 μM 2-
mercaptoethanol. The agonist peptide SIINFEKL (N4) and partial agonist SIIT-
FEKL (T4) (Peptide Synthetics) were added to culture medium at concentrations
stated in ﬁgure legends. Recombinant human TGFβ (R&D) was added to cultures
at 5 ng/ml unless otherwise stated and, where indicated, a TGFβ inhibitor
(SB431542, 2.5 μM, Abcam), Jak3 inhibitor (tofacitinib, 200 nM, Tocris
Bioscience), or recombinant human IL-2 (Peprotech) were also added. Transwell
experiments were performed using HTS Transwell 96 system 0.4 μm pore poly-
carbonate membrane (Corning). For measurement of IL-2, cells were stimulated
with peptide± TGFβ in the presence of blocking CD25 mAb (Biolegend) in order
to prevent IL-2 consumption. IL-2 in culture supernatants was measured using the
Mouse IL-2 ELISA Ready-SET-Go!® kit (eBioscience).
Immunoprecipitation and western blot. T cells were generated in vitro by sti-
mulating OT-1 control or Ptpn22−/− cells for 2d with 0.01 μM N4, washed, then
expanded for a further 6d in 20 ng/ml recombinant human IL-2 (Peprotech) fol-
lowed by treatment for 2.5 h± TGFβ (5 ng/ml). Cells were lysed in 1% TritonX-
100, 0.5% n-dodecyl-b-D-maltoside, 50 mM Tris-HCl, 150 mM NaCl, 20 mM
EDTA, 1 mM NaF, and 1 mM sodium orthovanadate containing protease inhibi-
tors. Samples were immunoprecipitated with anti-Ptpn22 antibody (clone D6D1H,
Rabbit mAb Cell Signaling Technology) coupled to Dynabeads prot G (10003D;
Life Technology). Western blots were performed on samples and membranes were
probed with anti-Ptpn22 rabbit mAb (clone D6D1H, cat CS14693S, dilution 1:1000
from Cell Signaling Technology) and anti-murine CSK antibody (clone 52, cat
610079, dilution 1:1000, from BD Transduction Labs) and proteins detected with
secondary Abs and visualized using infrared imaging system (Odyssey; LI-COR
Biosciences). For uncropped western blot image, see Supplementary Fig. 2.
NFAT translocation assay. Control and Ptpn22−/− OT-1 cells (2 × 106 cells) were
stimulated with T4 peptide (T4−6 M) ± TGFβ for 4 h at 37 °C. Cells were then lysed
and nuclear extracts prepared and analysed for NFATc1 using the TransAM
NFATc1 Transcription Factor assay kit according to the manufacturer’s instruc-
tions (Activemotif).
Calcium ﬂux. OT-1 cells (1 × 107 cells) were prestained with anti-CD8β (clone
eBioH35-17.2, cat 15266777, 1:400 dilution) in order to identify cell populations
prior to loading with 2 µM Indo-1 AM (Life Technologies) for 40 min at 37 °C in
PBS. Cells were resuspended in pre-warmed IMDM containing 1% FCS and
supplemented with 2.5 mM CaCl2 and 2.8 mM MgCl2. The baseline Ca2+ levels
were measured for 1 min before PE-labeled N4 dextramer (Immudex, Denmark)
was added to stimulate the cells. Some samples were pretreated with TGFβ (5 ng/
ml) 5 min before the addition of dextramer. Ionomycin (1 µg/ml) was added as a
positive control for measuring saturated Ca2+ levels. Data are represented as the
ratio of 398 nm (Indo-1 bound to Ca2+)/482 nm (unbound Ca2+) in OT-1 cells by
ﬂow cytometry and all data were acquired on an LSRII (BD Bioscience).
Cell lines. ID8 ovarian carcinoma cells were a gift from Dr K. Roby, University of
Kansas, USA23. EL4-OVA cells were provided by Dr K. Okkenhaug, Babraham
Institute, UK and EL4-OVAsTGFβRII cells were provided by Prof. J. Massagué,
Memorial Sloan Kettering Cancer Institute, New York, USA. All cell lines were
negative for mouse pathogens, including mycoplasma contamination (IMPACT
IV, IDEXX BioResearch).
ID8 tumor experiments. ID8 ovarian carcinoma cells23 were transduced with
retroviral constructs to express the ova-variant protein T4 (aminoacids 197–387).
ID8-T4 cells were maintained in IMDM supplemented with 10% FCS, 50 μM 2-
mercaptoethanol, L-glutamine and antibiotics (100 U penicillin, 100 mg/ml strep-
tomycin, 0.5% ciproxin). For co-culture experiments, sub-conﬂuent ID8-T4 cells
were harvested and transferred to 48-well tissue culture plates at 2 × 104 cells/well.
Cells were allowed to settle and adhere to culture plates for 4 h then OT-I T cells
were added (2 × 105/well) and cells co-cultured for 48 h. For analysis of T cell
intracellular cytokine expression, Brefeldin A (2.5 mg/ml, Sigma) was added to
wells for the last 6 h of culture prior to staining using the antibodies described
above.
For in vivo T cell expansion studies, abdominal tumors were established using
107 ID8 cells injected i.p. to recipient CD45.1+/− CD45.2+/− mice. After 28 days,
OT-I CD45.1+/+ and Ptpn22−/− OT-I CD45.2+/+ T cells were mixed 1:1, stained
with CTV dye (Molecular Probes) and transferred i.p. to tumor-bearing or control
mice. After 3 days, peritoneal lavages were performed and tumor-induced T cell
proliferation assessed as described above.
For tumor rejection studies, ID8-T4 cells were stably transduced with Fireﬂy
luciferase-expressing lentiviral vector (kindly provided by M. Lorger, University of
Leeds) (ID8-T4-ﬂuc2). Abdominal tumors were established by injection of 5 × 106
ID8-T4-ﬂuc2 cells i.p. into B6 recipients. Quantiﬁcation of tumor growth was
performed via non-invasive bioluminescence imaging using IVIS Spectrum and
Living Image software (Perkin Elmer) on day 11 prior to adoptive T cell
transfer. T cells for transfer were generated in vitro by stimulating OT-1 control or
Ptpn22−/− cells for 2 days with 0.01 μM N4, washed, then their populations
expanded for a further 4 days in 20 ng/ml recombinant human IL-2 (Peprotech).
On day 12, 107 OT-1 control or OT-1 Ptpn22−/− effector CTLs cells were injected i.
p. into recipient tumor-bearing mice and tumor growth monitored by
bioluminescence imaging at various time points thereafter.
EL4 tumor experiments. EL4-OVA and EL4-OVAsTGFβRII cells were main-
tained in IMDM supplemented with 10% FCS, 50 μM 2-mercaptoethanol, L-
glutamine and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, 400 μg/ml
geneticin (G418) and 0.5% ciproxin). Tumor cells in log-phase growth were
resuspended in PBS and 106 cells were injected subcutaneously into the right dorsal
ﬂank. Expression of SIINFEKL/H-2Kb pMHC complexes in >97% EL4 cells was
veriﬁed by ﬂow cytometry using anti-SIINFEKL/H-2Kb antibody (25 D1.6). Tumor
growth was monitored at least twice weekly using calipers with tumor volume
calculated as length × width × the average of length and width measurement to
approximate the total volume of the subcutaneous tumor mass (mm3)41. Five days
after tumor cell injection, a time point at which 30–50% of animals presented with
palpable tumor mass, recipient mice were randomly divided into three groups.
Control mice received no adoptive cell transfer, whereas other groups received
adoptive transfer of 105 control or Ptpn22−/− OT-1 T cells by intravenous injec-
tion. Following 7–10 days, mice were killed, tumors resected and tumor mass
determined.
Statistical analysis. Prism software was used for Student’s t test (paired or
unpaired; two tails), two-way ANOVA with Tukey’s post test for multiple com-
parisons and χ2-test with Fisher’s exact post test.
Data availability. The data that support the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles and from the corre-
sponding authors upon reasonable request.
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